AC Immune (ACIU)
NASDAQ:ACIU
Want to see ACIU full AI Analyst Report?
Top Page
AC Immune SA
(NASDAQ:ACIU)
Select Model
Select Model
Rating:44Neutral
Price Target:
$2.50
▼(-16.94% Downside)
Action:Reiterated
Date:06/10/26
The score is driven primarily by weak financial performance (persistent losses, 2025 revenue decline, and a return to heavy cash burn despite low debt) and bearish technical conditions (below key moving averages with negative MACD). Valuation provides limited offset because the negative P/E is not informative and no dividend yield is available.
Positive Factors
Strategic pharma collaborations with milestone upside
Material partnerships with large pharma (Takeda) create durable non-dilutive funding and external validation of lead programs. Contractual milestone structure can fund development, de-risk programs by sharing costs and provide sizeable upside if clinical readouts progress as planned.
Negative Factors
Structural unprofitability and volatile cash generation
The company remains loss-making with operating deficits translating into negative operating and free cash flow in 2025. Such persistent cash burn makes long-term program continuity contingent on timely partner payments, grants or capital markets, raising financing risk for multi-year trials.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic pharma collaborations with milestone upside
Material partnerships with large pharma (Takeda) create durable non-dilutive funding and external validation of lead programs. Contractual milestone structure can fund development, de-risk programs by sharing costs and provide sizeable upside if clinical readouts progress as planned.
Read all positive factors
AC Immune SA (ACIU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$244.26M
Dividend YieldN/A
Average Volume (3M)298.49K
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue Growth-85.87%
EPS Growth-41.37%
CountryUS
Employees133
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.67
Shares Outstanding101,773,575
10 Day Avg. Volume321,042
30 Day Avg. Volume298,491
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)5.58
Price to Sales (P/S)70.23
P/FCF Ratio-3.74
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue49.10
Enterprise Value/Gross Profit49.10
Enterprise Value/Ebitda-2.58
Forecast
1Y Price Target
$12.00Price Target Upside298.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$30.86M
AC Immune SA Business Overview & Revenue Model
Company Description
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding...
How the Company Makes Money
AC Immune primarily makes money through research collaborations and licensing arrangements with larger pharmaceutical partners rather than through product sales (as a clinical-stage company). Its revenue model typically includes: (1) upfront payme...
AC Immune SA Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
33
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.57M | 27.31M | 14.80M | 3.94M | 0.00 |
| Gross Profit | 3.57M | -35.26M | -39.80M | 3.94M | 0.00 |
| EBITDA | -67.75M | -48.62M | -51.83M | -68.03M | -70.01M |
| Net Income | -70.45M | -50.92M | -54.23M | -70.75M | -73.00M |
Balance Sheet | |||||
| Total Assets | 154.43M | 230.91M | 182.81M | 185.94M | 261.44M |
| Cash, Cash Equivalents and Short-Term Investments | 91.52M | 165.49M | 103.05M | 122.59M | 198.22M |
| Total Debt | 4.55M | 5.43M | 3.50M | 2.80M | 2.91M |
| Total Liabilities | 109.49M | 118.64M | 22.17M | 16.95M | 29.46M |
| Stockholders Equity | 44.93M | 112.27M | 160.64M | 168.99M | 231.98M |
Cash Flow | |||||
| Free Cash Flow | -67.01M | 65.27M | -61.21M | -74.81M | -68.32M |
| Operating Cash Flow | -66.15M | 65.84M | -60.41M | -73.57M | -65.69M |
| Investing Cash Flow | 60.69M | -105.29M | 65.64M | 23.76M | -53.66M |
| Financing Cash Flow | -974.14K | -1.12M | 43.25M | -1.35M | 40.75M |
AC Immune SA Technical Analysis
Negative
3.01
Price Trends
2.77
Negative
2.86
Negative
2.97
Negative
Market Momentum
-0.13
Negative
43.56
Neutral
78.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACIU, the sentiment is Negative. The current price of 3.01 is above the 20-day moving average (MA) of 2.47, above the 50-day MA of 2.77, and above the 200-day MA of 2.97, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 43.56 is Neutral, neither overbought nor oversold. The STOCH value of 78.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACIU.
AC Immune SA Risk Analysis
AC Immune SA disclosed 82 risk factors in its most recent earnings report. AC Immune SA reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AC Immune SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.41B | -5.33 | -85.61% | ― | ― | -68.11% | |
46 Neutral | $243.66M | -3.83 | 85.78% | ― | 20.08% | 14.06% | |
46 Neutral | $785.15M | >-0.01 | 87.31% | ― | ― | -1004.74% | |
44 Neutral | $244.26M | -2.88 | -123.98% | ― | -85.87% | -41.37% | |
44 Neutral | $412.81M | -2.42 | -677.38% | ― | 7.97% | 59.82% | |
44 Neutral | $194.29M | -1.54 | -295.17% | ― | -79.15% | 5.68% |
* Healthcare Sector Average
ACIU
AC Immune SA
2.40
0.52
27.66%
EDIT
Editas Medicine
2.69
0.47
21.17%
ALEC
Alector
1.75
0.28
19.05%
MLTX
MoonLake Immunotherapeutics
19.21
-24.29
-55.84%
FHTX
Foghorn Therapeutics
4.15
-0.57
-12.08%
VOR
Vor Biopharma
14.49
9.69
201.88%
AC Immune SA Corporate Events
AC Immune Shareholders Back Capital Band, Governance Slate and Pay Caps at June 11 AGM
Jun 11, 2026
On June 11, 2026, AC Immune SA held its Annual General Meeting, where shareholders approved the company’s 2025 IFRS consolidated and statutory financial statements and endorsed the 2025 compensation report, despite the year’s CHF 67.6 ...
AC Immune Secures $4 Million Goradia Foundation Grant to Extend Phase 2 Parkinson’s Trial
Jun 11, 2026
On June 11, 2026, AC Immune SA said it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation to extend Part 1 of its ongoing Phase 2 VacSYn trial of ACI-7104, an anti-alpha-synuclein active immunotherapy, ...
AC Immune Sets June AGM and Reshapes Leadership as Long-Serving CEO Retires
May 15, 2026
AC Immune has convened its 2026 Annual General Meeting for June 11, 2026, publishing the invitation and proxy materials and asking shareholders to vote on 2025 financial statements, compensation resolutions, director re-elections and amendments to...
AC Immune CEO and Co-Founder Andrea Pfeifer to Retire at June 11 AGM; Board Chair Martin Zügel Named Interim Chief
May 12, 2026
On May 12, 2026, AC Immune announced that co-founder and long-serving Chief Executive Officer Dr Andrea Pfeifer will retire from her role at the company’s Annual General Meeting on June 11, 2026, after a 23-year tenure. The board emphasized ...
AC Immune Triggers $12 Million Takeda Milestone as Final ABATE Cohort Starts in Alzheimer’s Trial
Apr 30, 2026
On April 30, 2026, AC Immune SA reported that it had dosed the first patients in Cohort AD4 of its ongoing Phase 1b/2 ABATE trial of ACI-24, an anti-amyloid beta active immunotherapy for prodromal Alzheimer’s disease and adults with Down syn...
AC Immune Posts Q1 2026 Update, Extends Cash Runway and Advances Neurodegeneration Pipeline
Apr 30, 2026
On April 30, 2026, AC Immune reported first-quarter 2026 financial and corporate updates, highlighting a cash position of CHF 74.8 million as of March 31, 2026, providing runway into the fourth quarter of 2027 and reflecting reduced RD spending af...
AC Immune Secures Amended Tau Drug Collaboration with Lilly, Adds CHF 10 Million Upfront
Apr 7, 2026
On April 7, 2026, AC Immune SA announced it had amended its 2018 license and collaboration agreement with Eli Lilly to advance Tau aggregation inhibitor small molecules, including new lead Morphomer Tau candidates and backup compounds, for potenti...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.